Treatment of renal cell carcinoma with intra-arterial administration of SMANCS dissolved in Lipiodol.
Patients 1 with an unresectable clear-cell carcinoma of the kidney was treated by intra-arterial administration of SMANCS dissolved in an oily medium, Lioidol, (SMANCS/Lipiodol). It was previously shown that targeting chemotherapy could be achieved for hepatoma by the arterially administered SMANCS/Lipiodol. In this study, SMANCS/Lipiodol was administered for renal cancer and the selective remaining of SMANCS/Lipiodol in renal cancer was observed in this patient. Patient 1, after three years and five months of repeated arterial injection of the drug, the patient's physical condition recovered sufficiently, reduction in tumor size was observed and the tumor became resectable. Patient 2 with renal carcinoma (4 cm in diameter) was treated by intra-arterial injection of SMANCS/Lipiodol and resected for prevention of postoperative recurrence. More than 90% of the tumor showed necrosis. Definite anticancer effects of the preoperative arterial administration of SMANCS/Lipiodol can be observed both clinically and histologically.
Noda
S
S
Department of Urology, Kurume University of Medicine, Japan.
Konno
S
S
Tanaka
J
J
Yamada
M
M
Yoshitake
N
N
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004337:Drug Carriers; D004338:Drug Combinations; D005260:Female; D005663:Furans / Q000008:administration & dosage*; D006801:Humans; D007269:Injections, Intra-Arterial; D007459:Iodized Oil; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009336:Necrosis; D011137:Polystyrenes / Q000008:administration & dosage* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D009353:Zinostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000627:therapeutic use
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004337:Drug Carriers; D004338:Drug Combinations; D005663:Furans; D008299:Maleic Anhydrides; D011137:Polystyrenes; C044908:chromolipiodol; C035755:poly(maleic acid-styrene)neocarzinostatin; D007459:Iodized Oil; D009353:Zinostatin